The physiological effects of nitroglycerin as a potent vasodilator have long been documented. However, the molecular mechanisms by which nitroglycerin exerts its biological functions are still a matter of intense debate. Enzymatic pathways converting nitroglycerin to vasoactive compounds have been identified, but none of them seems to fully account for the reported clinical observations. Here, we demonstrate that nitroglycerin triggers constitutive nitric oxide synthase (NOS) activation, which is a major source of NO responsible for low-dose (1-10 nM) nitroglycerin-induced vasorelaxation. Our studies in cell cultures, isolated vessels, and whole animals identified endothelial NOS activation as a fundamental requirement for nitroglycerin action at pharmacologically relevant concentrations in WT animals.
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endothelial NOS ͉ neuronal NOS ͉ blood pressure I t has been Ͼ150 years since the effect of nitroglycerin as a potent vasodilator was first reported (1) . Since then, intense research has led to extensive and well documented literature regarding nitroglycerin's physiological effects (2) (3) (4) and the identity of its derived metabolites in cells, tissues, laboratory animals, and humans (5, 6) . Although much of nitroglycerin's pharmacology is known, the mechanisms through which nitroglycerin acts on the endothelium and the heart as well as the enzymatic pathways leading to its bioactivation are still controversial and under intense investigation. A number of hypotheses for nitroglycerin bioconversion in vivo have been formulated, implicating a multitude of enzymes such as GST (6, 7) , oxidoreductases (8) , and mitochondrial aldehyde dehydrogenase (9, 10) in the bioconversion of nitroglycerin to NO and/or other vasoactive compounds. For example, GST has been shown to catalyze the transnitration of lower thiols in the presence of nitroglycerin (6, 7) . Xanthine oxidase and mitochondrial aldehyde dehydrogenase (which are closely related oxidoreductases) have been found to mediate nitroglycerin reduction to nitrite (11) and NO itself (8, 10) . Several intermediate compounds, such as partially nitrated glycerin, nitrite (11) , and nitrosothiols (6, 7) , have been indicated as precursors of nitroglycerin-derived NO, which is ultimately responsible for the observed effects on the vasculature. Collectively, these studies contributed to establishing nitroglycerin as a metabolismdependent NO donor. Although some pathways have received more attention than others, none of the above-mentioned mechanisms seems to satisfactorily delineate nitroglycerin's peculiar kinetic and pharmacological behavior, which is distinct from that of other well characterized NO donors such as sodium nitroprusside (12) . For instance, the nitrate groups of nitroglycerin are chemically resistant to rapid reduction because they are esters of nitrate. Also, minute doses of nitroglycerin [maximum plasma concentration Ϸ6 nM for 0.5 mg of nitroglycerin administered sublingually (13) ], which are comparable to the basal levels of free NO [Ϸ5 nM as free NO (14)], result in acute vasodilation momentarily after administration (15) . These facts suggest that the production of NO by the endothelium is much higher than the stoichiometric conversion of nitroglycerin to vasoactive compounds and that it happens considerably faster than expected from traditional metabolic conversion, which, in addition to drug absorption and distribution to organs, requires bioconversion and redistribution of the active compounds to the smooth muscle around the endothelium. Consistently, research data have demonstrated that maximal nitroglycerin-induced vasorelaxation happens within 1-3 min after administration (16) , whereas NO production from nitroglycerin metabolism is considerably slower with accumulation for Ͼ60 min (17) .
These observations suggest the existence of physiological mechanisms that are rapidly activated by nitroglycerin to amplify NO production. We hypothesized that nitroglycerin acts as an activator of signal transduction, whose effects are greatly amplified in vivo through constitutive NO synthase (NOS) activation, leading to rapid vasodilation. Contrary to this hypothesis are several studies that demonstrated that nitroglycerin potency is augmented in animals with impaired NOS activity (18) (19) (20) . However, the use of in vivo preparations in animals given high micromolar doses of nitroglycerin intravenously and treated with distinct antagonist compounds added significant complexity to the interpretation of possible direct effects of this compound in the vasculature. Also, for the present study, NOS inhibitors that have been previously reported to potentiate the vasorelaxant action of acetylcholine [ACh; an endothelial NOS (eNOS) activator] such as N G -nitro-L-argininemethyl ester (21, 22) and N G -monomethyl-L-arginine (23) have been avoided. The results presented herein strongly support the hypothesis of NOS activation as a significant route for nitroglycerinmediated vasodilation.
Results

Effects of NOS Inhibitors on Nitroglycerin-Mediated Decreases in Rat
Blood Pressure. According to Fig. 1 , a single sublingual administration of nitroglycerin caused an immediate and dramatic decrease in the mean diastolic blood pressure of anesthetized rats compared with pretreatment baselines. The effects on the systolic blood pressure were considerably attenuated. Interestingly, nitroglycerin effects peaked a few minutes after adminis-tration and were maintained for Ϸ10-20 min, after which they returned to the pretreatment basal levels (Fig. 1) . The NOS inhibitors aminoguanidine (AG) (Fig. 1B) and L-N 5 -(1-iminoethyl)ornithine dihydrochloride (L-NIO) (Fig. 1C) were extremely efficient in inhibiting the average diastolic arterial pressure decreases in all animals studied. Interestingly, the effect of AG (general NOS inhibitor) was more pronounced than L-NIO (more specific inhibitor to the eNOS isoform), possibly suggesting the participation (to a minor extent) of neuronal NOS (nNOS) in the nitroglycerin-induced vasodilation (compare Fig.  1 B and C) . Interestingly, in some animals, nitroglycerin induced a substantial (two of five animals) or moderate (one of five animals) hypertension, particularly in the systolic parameter, after an initial decrease of the systolic arterial blood pressure (Fig. 1) . This hypertensive effect of nitroglycerin is reflected in the large error bars observed after 40 min of monitoring (Fig. 1) . This effect was even more pronounced when nitroglycerin was administered together with the NOS inhibitors and, in particular, the general NOS inhibitor AG.
Nitroglycerin-Mediated Vasodilation Is Diminished by NOS Inhibitors.
Next, we investigated the effect of nitroglycerin and, more importantly, its effects in association with aminoguanidine and L-NIO on phenylephrine-preconstricted aortic ring dilation. As shown in Fig.  2 , nitroglycerin and ACh consistently induced a marked relaxation of the endothelium-covered aortic rings, which is in agreement with previous observations (24) (25) (26) . Pretreatment of the tissues with L-NIO completely inhibited ACh-dependent relaxation and diminished nitroglycerin-mediated relaxation at submicromolar doses (Fig. 2) . It is well established that ACh stimulates vasodilation through eNOS activation as has been demonstrated with NOS inhibitors (24, 25) . AG also partially inhibited vasodilation mediated by both ACh and nitroglycerin (Fig. 2) . Consistent with NOS involvement, nitroglycerin-induced vasorelaxation at concentrations of 1-10 nM was considerably attenuated by the presence of two NOS inhibitors, furnishing compelling evidence for a common mechanism shared by nitroglycerin and ACh (Fig. 2) . Taken together, these results are consistent with NOS involvement in nitroglycerin-mediated vasorelaxation.
To further confirm the endothelium as a source of NO in the case of nitroglycerin stimulation, experiments were repeated with aortic rings from which the endothelium had been removed. In this case, vasodilation was abrogated at nanomolar concentrations of nitroglycerin. At higher doses of nitroglycerin, vasodilation could be observed, demonstrating that nitroglycerin may act directly through bioactivation after conversion by enzymes such as aldehyde dehydrogenase, GST, and others present in the smooth muscle. It is known that nitroglycerin effects are biphasic on isolated blood vessels and depend on the concentration administered. These two phases have been designated low K m pathway (dependent on nitroglycerin doses Ͻ1 M) and high K m pathway (dependent on nitroglycerin doses Ͼ1 M) (for a review see ref. 27 ). We interpreted the results shown in Fig. 2 as vasodilation being dependent on two independent processes, one caused by NOS activation, which dominates at lower nitroglycerin concentrations (the lower K m pathway), and one that is metabolism-driven, which operates at higher nitroglycerin concentrations (the high K m pathway). Indeed, removal of the endothelia or eNOS inhibitors worked equally well in inhibiting nitroglycerin-dependent vasodilation at concentrations Ͻ100 nM. Above this concentration, removal of the endothelia or eNOS inhibitors did not attenuate nitroglycerin's vasorelaxant activity. Of note is the fact that in excised aortic rings, all of the tissue is, to some extent, exposed to nitroglycerin added to the buffer. In vivo, the endothelium would be a further barrier, restricting nitroglycerin contact with the smooth muscle cells. This process may make the low K m pathway more important even at higher concentrations of nitroglycerin (Ͼ1 M). After a single administration of 0.5 mg of nitroglycerin sublingually, the concentration of nitroglycerin in the plasma rapidly reaches 5-10 nM (13) . Nitroglycerin concentrations in the plasma can be significantly increased by i.v. administration, but even in this case, the effective concentration of the drug that reaches the smooth muscle and is there metabolized remains to be established. The effect of the vehicle acetonitrile was also tested. As shown in the Fig. 2 Inset, acetonitrile had a slight inhibitory effect on the ACh-induced vasodilation and did not cause any vasodilation per se at the tested concentrations.
Time Course of Nitroglycerin-Induced Vasorelaxation of Endothelial-
Intact and Endothelial-Denuded Aortic Rings. Signal transduction events generally depend on minute concentrations of the signal molecule and take place almost immediately on contact. To evaluate nitroglycerin as a potential signal transduction activator, endothelium-intact and endothelium-denuded aortic rings were exposed to 1 nM (low dose) and 300 nM (high dose) nitroglycerin. As seen in Fig. 3 , brief exposures (1-10 min) of the endothelium-denuded rings to 1 nM nitroglycerin did not elicit vasodilation, in contrast to the endothelium-intact rings, which promptly reacted to the nitrate even at 1 min after nitroglycerin addition. At 300 nM concentrations, both endothelium-intact and endothelium-denuded rings reacted to nitroglycerin, suggesting that at high nitrogycerin doses, enough bioactivation through metabolism-driven routes takes place to lead to vasodilation. Interestingly, however, endothelium-denuded rings exhibited significantly decreased response to nitroglycerin at the 1-and 2-min exposure time points, revealing that even at the high nitroglycerin doses, signal transduction pathways significantly contribute at the initial stages of vasodilation (Fig. 3) . It is important to highlight that the speed at which metabolic-driven pathways operate is directly proportional to the available concentration of the metabolite to the enzymes under consideration. At pharmacologically relevant doses (1-10 nM), it appears that metabolism is too slow to significantly account for the observed effects on the isolated vascular tissue.
Time Course of Nitroglycerin-Induced eNOS Activation in a Human
Endothelial Cell Line. To compare the time course of eNOS phosphorylation with the available data about nitroglycerin pharmacokinetics in humans, human umbilical cord endothelial cell (HUVEC) cultures were used. It has been demonstrated that eNOS-mediated NO production is preceded by eNOS phosphorylation at Ser-1177 (28) (29) (30) and dephosphorylation at Thr-495 (30, 31); therefore, both sites were used as indicators of eNOS activation. For our studies, nitroglycerin was added to the culture media and left undisturbed for different times, followed by PBS wash and lysis. As shown in Fig. 4 , cells treated with nitroglycerin presented marked phosphorylation at Ser-1177, which peaked at 5 min after nitroglycerin addition, then subsequently declined (see gradual fading of the bands' intensities). Experiments using ACh as a positive control consistently rendered considerable phosphorylation of Ser-1177 in opposition to the barely detectable signal arising from nonstimulated HUVECs (data not shown). Conversely, phosphorylation at Thr-495 was detectable in the nonstimulated cells and faded upon nitroglycerin stimulation, consistent with nitroglycerin-induced eNOS activation. These data demonstrate that eNOS phosphorylation peaked a few minutes after nitroglycerin addition to the cell cultures, which is fully consistent with the maximal decrease in the blood pressure and the immediate relief experienced by patients treated with nitroglycerin. through which nitroglycerin mediates vasorelaxation independent of metabolism. To gather further proof for this hypothesis, we next investigated NOS phosphorylation in the rat aortae excised after 3 min of nitroglycerin administration. As seen in Fig. 5 , treatment of anesthetized rats with nitroglycerin (acetonitrile solutions or in pills) induced a marked increase in eNOS phosphorylation at Ser-1177, an index associated with increased enzyme activity (32) (33) (34) . Without nitroglycerin, neither acetonitrile (Fig. 5 ) nor saline (data not shown) injections gave increased levels of eNOS phosphorylation. It has been demonstrated in the literature that eNOS knockout mice are slightly more responsive to nitroglycerin than WT ones, which imposes a clear conflict with the hypothesis that eNOS activation is required for nitroglycerin-induced vasorelaxation (35, 36) . It is also known that such animals express nNOS at levels markedly higher than WT controls (37) . For that reason, we performed additional experiments to verify whether nitroglycerin also modulates neuronal NO activity in rats, mice, and eNOS knockout mice. As shown in Fig. 5 , rats treated with nitroglycerin exhibited considerable phosphorylation of nNOS at Ser-852. In the mice, a similar phosphorylation pattern was observed in which phosphorylation of both eNOS (at Ser-1177) and nNOS (at Ser-852) isoforms was considerably enhanced after treating the animals with nitroglycerin (Fig. 6) . In eNOS knockout mice, nNOS phosphorylation induced by nitroglycerin was clearly observed (Fig. 7) . These data strongly suggest that the modulation of NOS activity plays a significant role in mediating nitroglycerininduced vasorelaxation. The significantly higher levels of nNOS in eNOS knockout animals together with nitroglycerin-induced nNOS phosphorylation indicate that, in eNOS knockout animals, the nNOS isoform may compensate for the absence of eNOS that renders eNOS knockout animals fully responsive to nitroglycerin at low pharmacologically relevant concentrations, in full agreement with published observations (35, 36) . Although the mechanisms by which nNOS activity is controlled by phosphorylation have yet to be investigated in the vasculature, our data suggest that nNOS is modulated by nitroglycerin.
Discussion
Nitroglycerin's mode of action has received considerable attention for several decades. Despite the extensive and well described physiological effects that nitroglycerin exerts in vivo, limited progress has been achieved in unraveling its modes of action. Part of the problem resides in the fact that multiple metabolic routes have been demonstrated to lead to nitroglycerin bioactivation. This literature contributed to build a preconception that nitroglycerin or its activated form acts as a NO donor. The fact that nitroglycerin does not resemble any endogenously produced molecule, might have precluded much investigation of metabolism-independent physiology. The fact that maximal concentrations of nitroglycerin administered to humans, even if immediately metabolized, are not likely to raise NO levels beyond the basal physiological level (5-20 nM) also implies the requirement for an amplification step in vivo.
Another point to consider is that metabolism would need to be nearly instantaneous to account for the fast relief experienced by patients upon nitroglycerin administration. We thus decided to focus our studies on unraveling the role of NOS as a signal amplifier involved in nitroglycerin-induced Pi-nNOS Pi-eNOS Anesthetized rats were treated with acetonitrile (vehicle control) or nitroglycerin (GTN; at the indicated concentrations) for 3 min before aorta excision. Proximal, thoracic, and mesentheric portions of the artery were cleaned of connective tissue and fat. The artery was then washed once in 0.1 M PBS buffer, pH 7.4, containing phosphatase-and protease-inhibitor cocktails. Immediately after washing, aortae were frozen at liquid nitrogen temperature and pulverized. Artery powder was resuspended in wash buffer containing 0.1% Triton-X and 0.5% SDS. Homogenate protein concentrations were determined, and 40 g of protein per lane was applied. Western blots were developed by using Santa Cruz anti-NOS antibodies. Relative band intensity (a.u.) Fig. 6 . Nitroglycerin-induced eNOS/nNOS phosphorylation in the mouse aortae. Anesthetized WT mice were treated with acetonitrile (vehicle control) or nitroglycerin (GTN; at the indicated concentrations) for 2 min before aorta excision. Proximal, thoracic, and mesentheric portions of the artery were cleaned of connective tissue and fat. The artery was then washed in 0.1 M PBS buffer, pH 7.4, containing phosphatase-and protease-inhibitor cocktails. Immediately after washing, aortae were frozen at liquid nitrogen temperature and pulverized. Artery powder was resuspended in wash buffer containing 0.1% Triton-X and 0.5% SDS. Homogenate protein concentrations were determined, and 40 g of protein per lane was applied. Western blots were developed by using Santa Cruz anti-NOS antibodies.
vasorelaxation. Through several lines of evidence, we demonstrated that eNOS and nNOS modulation by nitroglycerin is involved in the translation of nitroglycerin action. First, we showed that NOS inhibitors such as AG and L-NIO inhibit nitroglycerin-induced decreases in the arterial blood pressure of anesthetized rats (Fig. 1) . Consistently, AG and L-NIO were efficient in attenuating the response of isolated aortic ring preparations to low concentrations of nitroglycerin (Fig. 2) . Finally, detailed experiments were conducted at the molecular level to detect eNOS and nNOS phosphorylation in the aortae of rats, mice, and eNOS knockout mice (Figs. 5-7 ). These data demonstrated that eNOS is phosphorylated at Ser-1177 in the rats and mice treated with nitroglycerin, indicating nitroglycerininduced eNOS activation. We were also able to demonstrate that nitroglycerin induces the phosphorylation of nNOS at Ser-852 in the rats and mice, confirming the role of both constitutive isoforms of NOS in the mediation of nitroglycerin-induced vasorelaxation. As eNOS knockout mice have been previously demonstrated to be fully responsive to nitroglycerin, studies were performed to evaluate nNOS phosphorylation in those animals as well because eNOS knockout mice have been shown to overexpress the nNOS isoform. Consistent with published observations regarding eNOS-knockout animals, nitroglycerin treatment led to a remarkable phosphorylation of nNOS in those animals, suggesting that in the case of eNOS knockout mice, nNOS may serve to compensate the eNOS deficiency. Consistent with clinical observations, the time course of eNOS activation in HUVECs exposed to nitroglycerin happened within 3 min after nitroglycerin addition to the cell culture media, which closely matches the time for maximal nitroglycerin effects in animals (compare Figs. 1 and 4) . In regard to the isolated aortic rings, vasodilation was always observed in the case of the excised blood vessels treated with high doses of nitroglycerin (high K m pathway). In addition, nitroglycerin-induced vasodilation depended on the presence of the endothelium at low (1 nM) but not high (300 nM) nitroglycerin doses (Fig. 3) . Even at the high dose (300 nM), endothelium-denuded vessels' reactivity to nitroglycerin was attenuated when the tissues were briefly (1-2 min) exposed to the nitroglycerin (Fig. 3) , further indicating that at low doses (1-10 nM) signal transduction pathways are dominant in mediating vasodilation, and NO activation might be the event leading to the fast initial vasodilation observed shortly after nitroglycerin administration. Importantly, at the higher nitroglycerin doses (300 nM), vasodilation was independent of the endothelium and could not be abrogated by NOS inhibitors (Figs. 2 and 3 ). These findings suggest that nitroglycerin is bioactivated and exerts physiological effects through its metabolism at higher doses, which is consistent with findings of multiple enzyme-dependent ways to activate nitroglycerin (6, 8, 9) . Nevertheless, taken together, our experiments demonstrated that such pathways dependent on metabolism are not likely to be the major routes operating in vivo at therapeutic nitroglycerin doses (1-10 nM). In fact, the use of NOS inhibitors attenuated nitroglycerin's effects on arterial blood pressure in the rat even at the doses administered, which are higher than those used for clinical purposes.
Interestingly, it has been reported that maximal effects of nitroglycerin on human volunteers' hemodynamic parameters (2-5 min) coincided with peak concentrations of nitroglycerin in the plasma (38) of such patients and not with the peak concentrations of nitro glycerin (GTN) metabolites such as 1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate (Ϸ15 min) (13) .
The data presented here represent a paradigm in one of the most long-lived debates in medical literature and are likely to furnish further insight into the molecular mechanisms underlying nitrate resistance.
Materials and Methods
Chemicals. Nitroglycerin (1 mg/ml in acetonitrile) was purchased from Cambridge Isotope Laboratories. For vehicle control experiments, acetonitrile (chromatography grade) from Caledon Labs was used. Alternatively, Nitrotabs (Able Laboratories) (0.6 mg nitroglycerin per pill) were used for animal studies. L-NIO and AG hemisulfate were purchased from Calbiochem. AntinNOS, anti-phospho-nNOS (Ser-852), anti-eNOS, and anti-phospho eNOS (Ser-1177 and Thr-495) were from Santa Cruz and used according to the manufacturer's instructions. HUVECs were from Allcells and cultured as described (24) . All other chemicals used were analytical grade or superior.
HUVEC Cultures and Treatments. HUVECs were cultured according to the manufacturer's instructions. Media and supplements were purchased from the same company and used as recommended. Cells were treated with nitroglycerin (1 M) diluted into the media. After 3, 5, and 10 min, cells were lysed with lysis buffer [0.1 M phosphate buffer (pH 7.4), containing 100 mM NaCl, 0.1 mM EDTA, 0.1% SDS, 1% (wt/vol) sodium cholate, and 1% Triton X]. Lysis buffer was supplemented with Roche's protease inhibitor complete mini and Calbiochem's phosphatase inhibitor set III used as directed by the manufacturers.
Preparation of Rat Aortic Rings and Measurement of Relaxation. Rats were killed under CO2 asphyxia. The thoracic aorta was quickly dissected, cleaned of fat and connective tissue, and cut into four rings 4 -5 mm in length. The rings were mounted under 2 g of resting tension in 15-ml organ baths containing Krebs solution (115 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.14 mM KH2PO4, 1.19 mM MgSO4, 11.1 mM glucose, and 25 mM NaHCO3), gassed with 95% O2-5% CO 2, and maintained at 37°C. Preparations were allowed to equilibrate for 60 min with periodic washing before the experiments started. Tension was . Nitroglycerin-induced nNOS phosphorylation in the eNOS KO mice aortae. Anesthetized eNOS KO mice were treated with acetonitrile (vehicle control) or nitroglycerin (GTN; at the indicated concentrations) for 2 min before aorta excision. Proximal, thoracic, and mesentheric portions of the artery were cleaned of connective tissue and fat. The artery was then washed in 0.1 M PBS buffer, pH 7.4, containing phosphatase-and protease-inhibitor cocktails. Immediately after washing, aortae were frozen at liquid nitrogen temperature and pulverized. Artery powder was resuspended in wash buffer containing 0.1% Triton-X and 0.5% SDS. Homogenate protein concentrations were determined, and 40 g of protein per lane was applied. Western blots were developed by using Santa Cruz anti-NOS antibodies. measured with a force displacement transducer (Biopac Systems MP100). In some experiments, the endothelium of aortic rings was removed by gently rubbing the intimal surface; in others, care was taken to maintain the integrity of the endothelium. Nonfunctional endothelium was tested by the inability of ACh (0.1 nM to 1 M) to induce relaxation of aortic rings precontracted with phenylephrine (0.1 M). Nitroglycerin (0.1 nM to 1 M) was added to the organ bath after the addition of the eNOS inhibitors, L-NIO (200 M) or AG (100 M). Aortic rings with functional endothelium exhibited at least 90% relaxation under identical conditions. Values are expressed as mean Ϯ SEM. Statistical comparisons were performed through two-way ANOVA, followed by the Bonferroni test, at a 0.05 significant level (using Graphpad Prism program, version 4).
Animal Studies. Blood pressure measurements. Male Sprague-Dawley rats weighing 150 -200 g were used throughout the study. In each set of experiments, rats were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (20 mg/kg). Blood pressure measurements were performed by the tail cuff method (model SC1000; Hatteras Instruments) by using blood pressure analysis application software (version 2.21). Rats were placed on a warm pad after anesthesia, and a cuff equipped with a photosensor device was fitted over the tail. The cuff was set with a maximum pressure of 220 mmHg. After 30 consecutive measurements (Ϸ 30 min), 4 mg of crushed NitroTab pill was given sublingually to the rats, and blood pressure was monitored for an additional 30 min. The inhibitors used included AG (25 mg/kg) and L-NIO (50 mg/kg), which were dissolved in saline (0.1 M, pH 7.0). NOS activation studies. Mice and rats were anesthetized with pentobarbital at surgical doses. After sleep, animals were treated with sublingual nitroglycerin (40 g/kg) dissolved in acetonitrile. After 3 min, the full-length aortae were excised and cleaned of fat and connective tissue. The aortae were then washed in PBS containing protease and phosphatase inhibitor cocktails and immediately frozen in liquid nitrogen. The frozen tissue was then pulverized and homogenized in lysis buffer [0.1 M PBS (pH 7.4) containing 0.1% Triton X, 0.1% SDS, 0.1 mM DTPA and 5 mM sodium cholate] supplemented with protease and phosphatase-inhibitor cocktails. Protein content in each sample was determined through the Bradford assay. Protein separation was performed through SDS/PAGE in 4 -12% Bis-Tris NuPAGE (Invitrogen), and electroblotted onto a nitrocellulose membrane. The membrane was blocked with a 2.5% BSA/2.5% casein solution in 1ϫ TBS buffer (pH 7.4) for 3 h at 4°C. After four washes with washing buffer (1ϫ TBS containing 0.05% Tween-20, 0.05% BSA, and 0.05% casein, pH 7.4), the membrane was incubated overnight with the primary antibodies at a typical dilution of 1:1,000. After that, the membrane was washed four times and incubated for 60 min with the appropriate secondary antibodies conjugated with alkaline phosphatase at a typical dilution of 1:2,500 in washing buffer. After four more washes, antibody-antigen complexes were detected by enhanced chemiluminescence (Nitro Block II, Tropix; and CDP-Star II), and the nitrocellulose membrane was exposed to x-ray film. Band densitometry was performed through the use of the software ImageJ (http://rsb.info.nih.gov/ij).
